47.83
-0.33 (-0.69%)
| Penutupan Terdahulu | 48.16 |
| Buka | 47.85 |
| Jumlah Dagangan | 347,043 |
| Purata Dagangan (3B) | 780,450 |
| Modal Pasaran | 1,228,861,184 |
| Harga / Buku (P/B) | 4.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -3.23 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.07% |
| Nisbah Semasa (MRQ) | 33.87 |
| Aliran Tunai Operasi (OCF TTM) | -84.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -53.00 M |
| Pulangan Atas Aset (ROA TTM) | -19.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -26.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Tourmaline Bio, Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | 1.0 |
| Purata | -1.25 |
|
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 21.93% |
| % Dimiliki oleh Institusi | 90.21% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (BMO Capital, 0.36%) | Pegang |
| 48.00 (Piper Sandler, 0.36%) | Pegang | |
| 48.00 (Truist Securities, 0.36%) | Pegang | |
| 48.00 (Guggenheim, 0.36%) | Pegang | |
| 48.00 (Chardan Capital, 0.36%) | Pegang | |
| 48.00 (HC Wainwright & Co., 0.36%) | Pegang | |
| 48.00 (LifeSci Capital, 0.36%) | Pegang | |
| 48.00 (Wedbush, 0.36%) | Pegang | |
| Median | 48.00 (0.36%) | |
| Rendah | 47.50 (Jefferies, -0.69%) | Pegang |
| Purata | 47.94 (0.23%) | |
| Jumlah | 9 Pegang | |
| Harga Purata @ Panggilan | 47.62 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BMO Capital | 15 Sep 2025 | 48.00 (0.36%) | Pegang | 47.65 |
| Piper Sandler | 11 Sep 2025 | 48.00 (0.36%) | Pegang | 47.60 |
| Chardan Capital | 10 Sep 2025 | 48.00 (0.36%) | Pegang | 47.60 |
| Guggenheim | 10 Sep 2025 | 48.00 (0.36%) | Pegang | 47.60 |
| HC Wainwright & Co. | 10 Sep 2025 | 48.00 (0.36%) | Pegang | 47.60 |
| Truist Securities | 10 Sep 2025 | 48.00 (0.36%) | Pegang | 47.60 |
| Jefferies | 09 Sep 2025 | 47.50 (-0.69%) | Pegang | 47.64 |
| LifeSci Capital | 09 Sep 2025 | 48.00 (0.36%) | Pegang | 47.64 |
| Wedbush | 09 Sep 2025 | 48.00 (0.36%) | Pegang | 47.64 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |